Blog
Cagrilintide UAE: Amylin Research Peptide Guide — Satiety, Weight and Where to Buy (2026)
·
·
6 min read
For research use only. Material is supplied as a lyophilized reference compound with HPLC purity verification.
- Key Facts at a Glance
- What Is Cagrilintide?
- How Does Cagrilintide Work?
- Cagrilintide Research: Key Clinical Evidence
- Cagrilintide vs GLP-1 Peptides
As research into next-generation weight management peptides accelerates, Cagrilintide has emerged as one of the most promising compounds in the field. A long-acting analogue of the naturally occurring hormone amylin, Cagrilintide works through a fundamentally different mechanism to GLP-1 receptor agonists — and when combined with them, produces additive effects that have driven significant research interest worldwide.
For UAE researchers investigating appetite regulation, satiety signalling, and metabolic dysfunction, this guide covers everything you need to know about Cagrilintide: its mechanism, the clinical research, dosing protocols, and where to buy pharmaceutical-grade Cagrilintide in Dubai and across the UAE.
02
What Is Cagrilintide?
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk and currently in Phase 3 clinical trials as part of the CagriSema combination (Cagrilintide + Semaglutide). Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. It plays a critical role in regulating postprandial glucose levels, gastric emptying, and satiety — complementing insulin’s glucose-lowering effects.
Native amylin has an extremely short half-life and self-aggregates rapidly, making it impractical for research. Cagrilintide solves this through structural modifications that dramatically extend its half-life to approximately 7 days — enabling once-weekly administration in clinical research protocols.
03 · Work
How Does Cagrilintide Work?
Latest research insights. No spam, ever.
Cagrilintide activates amylin receptors — a family of receptors formed by the combination of calcitonin receptors with receptor activity-modifying proteins (RAMPs). These receptors are found in key brain regions involved in appetite regulation, including the area postrema, nucleus tractus solitarius, and hypothalamus.
- Satiety enhancement: Cagrilintide activates central amylin receptors to promote feelings of fullness and reduce meal size
- Gastric emptying reduction: Slows the rate at which the stomach empties, extending postprandial fullness and blunting glucose spikes
- Glucagon suppression: Reduces postprandial glucagon secretion, improving glycaemic control complementary to insulin
- Body weight reduction: Through its central appetite-suppressing effects, Cagrilintide produces significant and sustained reductions in body weight in research models
- Complementary to GLP-1: Amylin and GLP-1 receptors are expressed in overlapping but distinct brain circuits, making Cagrilintide highly complementary to GLP-1 receptor agonists like glp-3 and semaglutide
04 · Research
Cagrilintide Research: Key Clinical Evidence
CALM Phase 2 Trial
The CALM Phase 2 trial evaluated Cagrilintide monotherapy across four dose levels (0.3mg, 0.6mg, 1.2mg, 2.4mg) over 26 weeks in adults with overweight or obesity. Results published in The Lancet showed dose-dependent weight reductions of up to 10.8% from baseline at the highest dose — a substantial effect for a monotherapy, with a favourable safety profile.
CagriSema Combination Research
The most compelling Cagrilintide research involves its combination with semaglutide as CagriSema. Phase 2 results published in The Lancet showed CagriSema produced mean weight reductions of 15.6% over 32 weeks — significantly greater than either compound alone, confirming the complementary mechanism hypothesis. Phase 3 REDEFINE trials are currently ongoing.
Glycaemic Control
In addition to weight effects, Cagrilintide research has shown significant improvements in HbA1c, fasting glucose, and postprandial glucose excursions — effects consistent with its amylin mechanism of reducing gastric emptying and suppressing glucagon.
05 · GLP-1
Cagrilintide vs GLP-1 Peptides
| Peptide | Receptor Target | Primary Mechanism | Weight Loss (mono) |
|---|---|---|---|
| Cagrilintide | Amylin receptor | Satiety, gastric emptying, glucagon suppression | ~10-11% |
| GLP-3 | GLP-1/GIP/Glucagon triple agonist | Appetite, insulin, energy expenditure | ~17-24% |
| Semaglutide | GLP-1 receptor | Appetite, insulin secretion | ~15% |
| CagriSema (combo) | Amylin + GLP-1 | Complementary dual mechanism | ~15-22% |
UAE researchers frequently compare Cagrilintide to glp-3 — which targets three receptors simultaneously for a different metabolic profile.
06 · Dosing
Cagrilintide Dosing Protocol (Research Reference)
For research reference only. Cagrilintide is not approved for human use and is in Phase 3 clinical trials.
In clinical trials, Cagrilintide has been administered as a once-weekly subcutaneous injection, with dose escalation from 0.3mg through to 2.4mg over several weeks. Its 7-day half-life makes weekly administration appropriate for maintaining steady-state plasma levels. Emirates Peptides supplies Cagrilintide in 5mg vials.
Reconstitute with bacteriostatic water and use our peptide calculator for accurate concentration.
Storage Guidelines
Lyophilised:
Store at 2-8°C, protect from light
Reconstituted:
Store at 2-8°C, use within 28 days
Do not freeze reconstituted solution
07
Where to Buy Cagrilintide in the UAE
Emirates Peptides supplies pharmaceutical-grade Cagrilintide in 5mg lyophilised vials, HPLC-verified at ≥99% purity. Fast delivery across the UAE and GCC.
- ✅ COA-verified, ≥99% purity
- ✅ Delivery to Dubai, Abu Dhabi, Sharjah and all UAE emirates
- ✅ GCC shipping available
- ✅ Cash on delivery in Dubai
- ✅ Discreet packaging
08 · Questions
Frequently Asked Questions
Is Cagrilintide better than semaglutide?
They work through different mechanisms — amylin receptor vs GLP-1 receptor. Research shows they are complementary rather than competitive, with their combination (CagriSema) producing greater effects than either alone. The comparison depends entirely on the research endpoint being investigated.
Can Cagrilintide be combined with GLP-3?
This is an area of active pre-clinical research interest. GLP-3 targets GLP-1, GIP, and glucagon receptors while Cagrilintide targets amylin receptors — theoretically complementary pathways. Combination research is ongoing in pre-clinical settings.
Is Cagrilintide legal in the UAE?
Cagrilintide is supplied strictly for research use and is not a controlled substance in the UAE.
What is CagriSema?
CagriSema is the fixed-ratio combination of Cagrilintide and Semaglutide developed by Novo Nordisk. Phase 3 trials show greater weight reduction than either compound alone — typically reported as additive, not synergistic. The combination is one of the most-watched developments in metabolic research.
What is the typical Cagrilintide research dose?
Published research-protocol doses range from 0.3–2.4 mg weekly subcutaneous (as part of the CagriSema combination arm) up to 4.5 mg weekly for monotherapy research. The standard titration is slow — over 16+ weeks — to manage GI tolerability.
How is amylin different from GLP-1?
Both are gut-and-pancreas hormones that regulate satiety, but they act on different receptors. Amylin is co-secreted with insulin from pancreatic beta cells and acts on amylin receptors (AMY1/2/3) in the brainstem. GLP-1 is an incretin secreted from the gut and acts on GLP-1 receptors throughout the body. The two systems are biologically independent — which is why CagriSema produces additive effects.
Disclaimer: This article is for educational purposes only. Cagrilintide is sold strictly for laboratory research use. It is an investigational compound in Phase 3 clinical trials and is not approved for human use. This is not medical advice.
Was this article helpful?
🔬 Related Research Peptides
Explore Research-Grade Peptides
HPLC-verified, lab-tested peptides for your scientific research. Fast delivery across the UAE.
Browse All PeptidesRelated Articles
Selected Research References
Selected scientific references for research context only. Products remain for laboratory research use and are not for human use.
Emirates Peptides Research Team
A dedicated coalition of biochemists and clinical researchers focusing on advanced peptide synthesis and pharmacological applications. All data is verified against current clinical trials.
